SecBot SecBot

DMRA

Damora Therapeutics, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001800315 Biotech & Drug Discovery
$21.19 +0.10 (+0.47%)
Oct 26 4:00 PM ET · prev $21.09
Market cap
$1.3B
Small cap
Consensus
Buy
94% Buy or better · 16 analysts
Median target
$45.00
+112% · range $40.00–60.00
Next earnings
Oct 30
in 4 days · EPS est. −$0.43
1 year
+188.5%
from $7.34 · Oct 27
30 days
+2.1%
from $20.75
52-week range
$4.95–34.14
−38% from high · low Nov 7
Avg volume 20D
447.0K
Oct 6 spike 1.17M
Short interest
4.73M
≈7.7% of shares · +0.0%
Days to cover
4.8
at average volume
Insider net
+$245.5K
1 buyer · 1 seller · 12 mo
New fund stakes
0
Q2 2026 13F · 1 exit
SecBot read MIXED 4 reports · 90 days
Balance 1 bearish · 1 bullish · 2 neutral oldest → newest, height = score
Avg score ·High conf. 2/4 ·Next Earnings date, Oct 30, 2026
Strongest BULLISH Damora Therapeutics CEO Jarrett Jennifer made a single open-market purchase of 12,500 shares for $253K at…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBULLISH

    1 insider bought $252.9K at an average $20.23. 1 insider sold $7.3K.

  • InstitutionsBULLISH

    Q2 2026: 14 added (0 new), 5 trimmed or exited.

  • AnalystsBULLISH

    15 of 16 rate it Buy or better. Every target is above the price.

  • EstimatesFALLING

    Current-quarter EPS estimate −$0.395 → −$0.435 over 90 days. 1 up, 2 down in 30 days.

  • Short sellersSTEADY

    Short interest +0.0% to 4.73M shares. 4.8 days to cover, ≈7.7% of shares.

  • TrendDOWNTREND

    13% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
1
exit
FundMoveSharesValue
BlackRock, Inc.DOUBLED3,162,068$82.2M
STATE STREET CORPDOUBLED1,545,500$40.2M
Blackstone Inc.ADD1,002,971$26.1M
GEODE CAPITAL MANAGEMENT, LLCDOUBLED965,364$25.1M
UBS Group AGDOUBLED840,292$21.9M
NORTHERN TRUST CORPDOUBLED359,705$9.4M
GOLDMAN SACHS GROUP INCDOUBLED339,379$8.8M
CHARLES SCHWAB INVESTMENT MANAGEMENT INCDOUBLED142,137$3.7M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

16 analysts
Buy 94% rate it Buy or better
Strong Buy6Buy9Hold1Sell0Strong Sell0
12-month targets · 9 analysts

Price is below the lowest target. Median implies +112%.Targets as of Oct 26, 2026.

Recent actions
DateFirmActionRating
Sep 29, 2026Wedbush
REITERATE
REITERATEOutperform
Sep 25, 2026Guggenheim
MAINTAIN
MAINTAINBuy
Jul 30, 2026Wedbush
MAINTAIN
MAINTAINOutperform
Jul 27, 2026Jefferies
INITIATE
INITIATEBuy
Jul 21, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy
Jun 12, 2026Wedbush
REITERATE
REITERATEOutperform

Insider ledger

Form 4
$252.9K
bought · 1 insider
$7.3K
sold · 1 insider
+4.7%
vs their $20.23 cost
DateInsiderTypeValue
Sep 25, 2026
Jarrett Jennifer
Director, President and CEO
BUY$252.9K
Aug 12, 2026
Cheng Andrew
Director
AWARD30,350 sh
Jul 6, 2026
Winslow Garrett
General Counsel
SELL$7.3K
Jul 3, 2026
Winslow Garrett
General Counsel
EXERCISE680 sh
Mar 30, 2026
Jarrett Jennifer
See Remarks
AWARD1,500,000 sh
Mar 30, 2026
Jarrett Jennifer
See Remarks
AWARD500,000 sh
Mar 23, 2026
Turtle Cameron
Director
AWARD37,313 sh
Mar 23, 2026
Bruno Julianne
Director
AWARD37,313 sh

Earnings setup

Estimates
Oct 30
reports in 4 days
−$0.43
EPS estimate, this quarter
−10%
estimate change, 90 days
1↑ 2↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.43-$0.53–-$0.37+0.0%$0.00
Next Q-$0.47-$0.59–-$0.38-0.5%$0.00
Current FY-$1.90-$2.34–-$1.60-0.1%$0.00
Next FY-$2.17-$2.59–-$1.59-1.4%$0.00

Short side

FINRA· Sep 30, 2026
4,733,297
shares short
+0.0%
vs prior settlement
4.8
days to cover
≈7.7%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 12, 2026 SEC
A massive institutional cluster formed in Damora Therapeutics during Q2 2026, with 15 buyers accumulating $139.8M in…
INST-CLUSTER — Impact 3/10
Sep 28, 2026 SEC
Damora Therapeutics CEO Jarrett Jennifer made a single open-market purchase of 12,500 shares for $253K at $20.23/share…
INSIDER-BUY — Impact 5/10
Sep 25, 2026 Insider
Jarrett Jennifer bought 12,500 shares
Director, President and CEO @ $20.23 ($252.9K)
Sep 3, 2026 Other
Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Damora Therapeutics announced that it granted inducement equity awards to three newly hired, non-exe
Aug 13, 2026 SEC
Damora Therapeutics' shelf registration (File No. 333-292175) became effective on August 12, 2026, under the…
EFFECT — Impact 3/10
Aug 12, 2026 Insider
Cheng Andrew was granted 30,350 shares
Director
Jul 6, 2026 Insider
Winslow Garrett sold 245 shares
General Counsel @ $29.98 ($7.3K)
Jun 30, 2026 Inst.
BlackRock, Inc. — DOUBLED
3,162,068 shares ($82.2M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Oct 30, 2026
Earnings date
DMRA Q3 2026 Earnings Scheduled — 2026-10-30
Recent
Sep 3, 2026
Press release
Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Damora Therapeutics announced that it granted inducement equity awards to three newly hired, non-executive employees on September 1, 2026.
Aug 10, 2026
Earnings
Damora Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
– Initiated the Phase 1/1b CLARITY-101 clinical trial of DMR-001 in patients with mutant calreticulin (mutCALR)-driven essential thrombocythemia…
Aug 3, 2026
Press release
Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ: DMRA) (“Damora”), a biotechnology company working to fundamentally…
Aug 3, 2026
Earnings date
DMRA Q2 2026 Earnings Scheduled — 2026-08-03
Jul 17, 2026
Press release
Damora Announces Redomestication from Delaware to Cayman Islands
BOSTON, July 17, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (Damora or the Company) (NASDAQ: DMRA), a biotechnology company working to…

SecBot reports

6 filings · 2 press releases · 1 bullish · 1 bearish · 4 neutral
All DMRA filing & press-release reports (8)